October 2022 in “Frontiers in Bioengineering and Biotechnology” This study demonstrated that in a mouse model of androgenic alopecia, PLGA-DUT/siAR@DPCM nanoparticles effectively delivered drugs to hair follicles, suppressed androgen-related targets, promoted cell proliferation, and showed significant therapeutic effects with minimal adverse effects, suggesting their potential for clinical application.
January 2025 in “RSC Advances” This study reported that a new formulation of finasteride solid lipid nanoparticles, combined with LPC and NTC, enhanced hair growth in mice without visible skin reactions, suggesting it could effectively manage androgenetic alopecia.
January 2026 in “ACS Applied Bio Materials” This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.
This study found that a cholesterol-conjugated, cell-penetrating asiRNA targeting the androgen receptor effectively reduced hair loss and promoted hair growth in mouse models of androgenetic alopecia, suggesting potential as a novel treatment.
